BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
See today's BioWorld Asia
See today's BioWorld
Home
» Shanghai startup Eccogene bets on small molecules for NASH
To read the full story,
subscribe
or
sign in
.
Newco News
Shanghai startup Eccogene bets on small molecules for NASH
June 9, 2020
By
Elise Mak
BEIJING – After his role as associate director and head of chemistry at Eli Lilly and Co., Brandeis-trained Jingye Zhou founded Eccogene Inc. in Shanghai in 2018 to focus on developing small-molecule drugs for metabolism and immune-related diseases.
BioWorld
BioWorld Asia
Newco news